Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Mais filtros

Eixos temáticos
Intervalo de ano de publicação
1.
Lupus ; 30(6): 956-964, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33657919

RESUMO

BACKGROUND: Few prospective studies in cutaneous and systemic lupus erythematosus (CLE/SLE) assessed thalidomide-induced peripheral neuropathy (TiPN) incidence/reversibility, and most have not excluded confounding causes neither monitored thalidomide plasma levels. OBJECTIVES: To evaluate TiPN incidence/reversibility, coasting effect and its association with thalidomide plasma levels in CLE/SLE. METHODS: One-year prospective study of thalidomide in 20 CLE/SLE patients without pregnancy potential, with normal nerve conduction study (NCS), and excluded other PN causes. Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry. RESULTS: Twelve patients (60%) developed TiPN: 33.3% were symptomatic and 66.6% asymptomatic. Half of this latter group developed coasting effect (TiPN symptoms 1-3 months after drug withdrawal). The main predictive factors for TiPN were treatment duration ≥6 months (p = 0.025) and cumulative dose (p = 0.023). No difference in plasma thalidomide levels between patients with/without TiPN was observed (p = 0.464). After drug withdrawal, 75% symptomatic TiPN patients improved their symptoms. Seven TiPN patients underwent an additional NCS after drug withdrawal: 42.8% worsened NCS, 14.2% was stable, and 42.8% had improved NCS. CONCLUSION: Our data provides novel evidence of coasting effect in half of asymptomatic patients with TiPN. The irreversible nature of this lesion in 25% of TiPN patients reinforces the relevance of early NCS monitoring, and suggests thalidomide use solely as a bridge for other effective therapy for refractory cutaneous lupus patients.


Assuntos
Lúpus Eritematoso Cutâneo/tratamento farmacológico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Talidomida/efeitos adversos , Adulto , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Talidomida/sangue , Talidomida/uso terapêutico , Resultado do Tratamento , Suspensão de Tratamento
2.
Transpl Infect Dis ; 21(4): e13133, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31233669

RESUMO

Trichodysplasia spinulosa (TS) is a rare disease associated with immunosuppression and induced by a polyomavirus denominated Tricodisplasia Polyomavirus (TSPyV). We report a case of TS 6 months after kidney transplantation in a 65 years-old woman under immunosuppression therapy with prednisone, mycophenolate and tacrolimus. The patient developed follicular papules on the face with a thickening of the skin and alopecia of the eyebrows, leading to distortion of the face and a leonine appearance characteristic of the disease. The skin biopsy confirmed the clinical diagnosis and the presence of TSPyV DNA in the skin was detected. Staining for SV40 was positive. Immunosuppression was changed: mycophenolate was withdrawn, tacrolimus reduced and everolimus added. Intravenous cidofovir and later on leflunomide were added. Although the literature has reported clinical success with topical cidofovir, we were unable to use it because this drug is not available. There was an improvement of skin lesions and on cosmetic appearance. The patient had three rejections (one clinically diagnosed and two other biopsy proven), progressed with renal failure and graft loss. Retrospective analysis of stored urine and blood samples detected TSPyV DNA in some of those samples two months before the TS clinical development. This case highlights the TSPyV detection in blood and urine samples before the development of skin lesions.


Assuntos
Doenças do Cabelo/virologia , Transplante de Rim/efeitos adversos , Infecções por Polyomavirus/diagnóstico , Viremia/diagnóstico , Viremia/tratamento farmacológico , Idoso , DNA Viral , Feminino , Doenças do Cabelo/tratamento farmacológico , Humanos , Terapia de Imunossupressão/efeitos adversos , Imunossupressores , Rim/patologia , Infecções por Polyomavirus/urina , Estudos Retrospectivos , Pele/patologia , Pele/virologia , Transplantados
4.
Dermatol Online J ; 19(4): 6, 2013 Apr 15.
Artigo em Português | MEDLINE | ID: mdl-24021366

RESUMO

Psoriatic onychopachydermoperiostitis (POPP) syndrome characterizes a clinical variant of psoriatic arthritis originally described by Fournie et al in 1989. Both great toes are generally affected presenting with nail changes, painful swelling of the soft tissue close to the distal phalanx as well as specific radiologic changes such as periosteal reaction and bone erosions of the distal phalanges. Joint involvement is characteristically absent and classic psoriatic lesions may be associated. Painful symptoms may lead to severe functional and quality of life impairment. Traditional systemic treatment is generally frustrating. Here we report a female patient presenting POPP syndrome refractory to traditional systemic treatments and adalimumab, further presenting a favorable response to treatment with etanercept.


Assuntos
Artrite Psoriásica/diagnóstico , Dermatoses do Pé/diagnóstico , Onicólise/diagnóstico , Artrite Psoriásica/tratamento farmacológico , Artrite Psoriásica/patologia , Produtos Biológicos/uso terapêutico , Etanercepte , Feminino , Dermatoses do Pé/tratamento farmacológico , Dermatoses do Pé/patologia , Humanos , Imunoglobulina G/uso terapêutico , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Onicólise/tratamento farmacológico , Onicólise/patologia , Receptores do Fator de Necrose Tumoral/uso terapêutico , Síndrome , Dedos do Pé/patologia
6.
An Bras Dermatol ; 97(1): 63-74, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34838431

RESUMO

Generalized pustular psoriasis (von Zumbusch) is a rare and acute eruption characterized by multiple sterile pustules over an erythematous and edematous background, eventually associated with psoriasis vulgaris. Classically, it manifests as a potentially severe systemic picture and demands prompt diagnosis and intervention. The duration of each flare-up and intervals between the pustular episodes is extremely variable. Recently, genetic abnormalities have been identified mainly in the familial and early variants of this disease. The therapeutic arsenal is limited; however, new drugs being evaluated aim to control both pustular flare-ups and disease recurrences.


Assuntos
Exantema , Psoríase , Dermatopatias Vesiculobolhosas , Doença Aguda , Doença Crônica , Humanos , Psoríase/diagnóstico , Psoríase/tratamento farmacológico
7.
Vaccines (Basel) ; 9(5)2021 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-34068473

RESUMO

Psoriasis is an immune-mediated dermatosis usually associated with comorbidities. Treatment varies from topicals to systemic drugs and data on susceptibility to viral infections in psoriatic patients are scarce. The objectives of this study were to analyze psoriatic patients on different therapies who were at risk for COVID-19 for seroprevalence of SARS-COV-2, pro-inflammatory cytokine profile, comorbidities and outcomes in order to unveil the immunological mechanisms involved in the anti-viral response in patients with psoriasis. Seventy-five patients with psoriasis were divided according to treatment: immunobiologics, methotrexate, topicals and acitretin. Twenty healthy controls were included. Plasma samples were collected for: IgG SARS-COV-2 (ELISA); IL-27, IL-29 and IL-18 (ELISA); and IL-1ß, IL-17A, IL-6 and TNF (cytometric array). Seropositivity for SARS-COV-2 was detected in 24 out of 75 psoriasis patients and did not relate to COVID-19 symptoms and/or hospitalization, despite associated comorbidities. Psoriasis patients who were asymptomatic for SARS-COV-2 exhibited immune imbalance with high levels of IL-18, IL-17A and IL-6, and low levels of IL-27 compared to healthy controls. Psoriasis groups showed significant increased cytokine levels only in the group with immunobiologics. Despite immune deviations and lower IL-27, which has a potential antiviral impact, psoriatic patients did not exhibit complications related to COVID-19. An understanding of this kind of proinflammatory profile of psoriatic patients and of the lack of severe outcomes for COVID-19 is essential to establish novel therapeutic approaches and preventive measures, including with regard to the concomitance of viral infections.

8.
Pediatr Dermatol ; 27(4): 349-54, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20403118

RESUMO

Generalized pustular psoriasis is a rare form of psoriasis consisting of a generalized eruption of sudden onset with erythema and sterile pustules. In children, generalized pustular psoriasis is even more uncommon and may present as a severe and potentially life-threatening disorder. In this study, we present demographics, clinical aspects, treatment response, and follow-up of seven children with generalized pustular psoriasis. Retrospective study reviewing the records of seven children with generalized pustular psoriasis including age, gender, age of onset, presence of scalp and nail involvement, family history, concomitant diseases, precipitating factors, treatment modalities, and outcome. Age of first symptoms ranged from 1 month to 11 years. All patients received systemic retinoids at one time of the follow-up period. Other treatment modalities included immunosuppressive drugs, biologics, phototherapy, and sulfasalazine. Two patients presented with severe constitutional illness, secondary infection and septic shock, including one fatal outcome. All further cases have remained free of recurrences for a mean period of up to 3 years. In our study, generalized pustular psoriasis presented a wide clinical spectrum in children ranging from mild, asymptomatic outbreaks to more severe, life-threatening episodes. One fatality was observed. Children generally responded well to systemic retinoids. Further studies and long-term follow-up periods are needed to define potential trigger factors, efficacy and safety of different treatment modalities in children with generalized pustular psoriasis.


Assuntos
Psoríase/tratamento farmacológico , Psoríase/patologia , Antibacterianos/uso terapêutico , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/tratamento farmacológico , Produtos Biológicos/uso terapêutico , Criança , Pré-Escolar , Evolução Fatal , Seguimentos , Humanos , Imunossupressores/uso terapêutico , Recém-Nascido , Masculino , Doenças da Unha/tratamento farmacológico , Doenças da Unha/patologia , Fototerapia , Recidiva , Retinoides/uso terapêutico , Estudos Retrospectivos , Dermatoses do Couro Cabeludo/tratamento farmacológico , Dermatoses do Couro Cabeludo/patologia , Choque Séptico/diagnóstico , Choque Séptico/tratamento farmacológico , Sulfassalazina/uso terapêutico , Resultado do Tratamento
9.
Front Med (Lausanne) ; 7: 580677, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33178720

RESUMO

Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.

10.
Rev Assoc Med Bras (1992) ; 65(4): 493-508, 2019 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-31066801

RESUMO

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.


Assuntos
Anticorpos Monoclonais/administração & dosagem , Etanercepte/administração & dosagem , Fatores Imunológicos/administração & dosagem , Psoríase/tratamento farmacológico , Anticorpos Monoclonais/efeitos adversos , Brasil , Tomada de Decisão Clínica , Etanercepte/efeitos adversos , Humanos , Fatores Imunológicos/efeitos adversos , Psoríase/patologia , Fatores de Risco , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento
11.
Rev Assoc Med Bras (1992) ; 65(4): 530-534, 2019 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-31066805

RESUMO

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.


Assuntos
Anticorpos Monoclonais/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Imunossupressores/administração & dosagem , Psoríase/tratamento farmacológico , Acitretina/administração & dosagem , Acitretina/efeitos adversos , Anticorpos Monoclonais/efeitos adversos , Brasil , Tomada de Decisão Clínica , Ciclosporina/administração & dosagem , Ciclosporina/efeitos adversos , Fármacos Dermatológicos/efeitos adversos , Humanos , Imunossupressores/efeitos adversos , Metotrexato/administração & dosagem , Metotrexato/efeitos adversos , Psoríase/patologia , Índice de Gravidade de Doença , Fatores de Tempo , Resultado do Tratamento
12.
An Bras Dermatol ; 94(2 Suppl 1): 76-107, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31166402

RESUMO

Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The most common clinical manifestations are erythematous, scaling lesions that affect both genders and can occur on any anatomical site, preferentially involving the knees, elbows, scalp and genitals. Besides the impact on the quality of life, the systemic nature of the disease makes psoriasis an independent risk factor for cardiovascular disease, especially in young patients with severe disease. By an initiative of the Brazilian Society of Dermatology, dermatologists with renowned clinical experience in the management of psoriasis were invited to form a work group that, in a partnership with the Brazilian Medical Association, dedicated themselves to create the Plaque Psoriasis Diagnostic and Treatment Guidelines. The relevant issues for the diagnosis (evaluation of severity and comorbidities) and treatment of plaque psoriasis were defined. The issues generated a search strategy in the Medline-PubMed database up to July 2018. Subsequently, the answers to the questions of the recommendations were devised, and each reference selected presented the respective level of recommendation and strength of scientific evidence. The final recommendations for making up the final text were worded by the coordinators.


Assuntos
Psoríase/diagnóstico , Psoríase/terapia , Corticosteroides/uso terapêutico , Antralina/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Brasil , Inibidores de Calcineurina/uso terapêutico , Comorbidade , Ciclosporina/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Dermatologia , Combinação de Medicamentos , Feminino , Humanos , Masculino , Metotrexato/uso terapêutico , Fototerapia/métodos , Psoríase/epidemiologia , Índice de Gravidade de Doença , Sociedades Médicas , Fatores de Tempo , Vitamina D/análise
13.
Braz J Infect Dis ; 11(4): 388-9, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17873989

RESUMO

Ten patients with donovanosis were treated with thiamphenicol for two weeks. In eight of them, included two HIV infected patients, lesions healed. The safety profile of thiamphenicol makes it a useful and cost-effective agent in the management of donovanosis. Randomized controlled trials should be conducted with these treatment options.


Assuntos
Antibacterianos/uso terapêutico , Granuloma Inguinal/tratamento farmacológico , Doenças do Pênis/tratamento farmacológico , Tianfenicol/uso terapêutico , Seguimentos , Humanos , Masculino , Doenças do Pênis/microbiologia , Resultado do Tratamento
14.
Rev Inst Med Trop Sao Paulo ; 49(1): 55-8, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17384821

RESUMO

Use of antimicrobials for the treatment of gonorrhea started in 1930 with the utilization of sulfonamides. With the years other drugs were used for its treatment such as penicillin, tetracycline, spectinomycin, and others. Although highly specific in the beginning, these drugs, with time did not show anymore the expected therapeutic results because of aspects of chromosomal and plasmid-mediated resistance. The purpose of this study was to evaluate the susceptibility of Neisseria gonorrhoeae strains to six drugs used for its treatment (penicillin, tetracycline, cefoxitin, thiamphenicol, spectinomycin and ofloxacin) by the determination of minimal inhibitory concentrations of these drugs. We concluded that drugs, such as cefoxitin, thiamphenicol and spectinomycin still are excellent pharmacological agents for the treatment of gonorrhea. Penicillin, although still efficient, needs more attention regarding its use, as well as ofloxacin, because of the emergence of resistant strains. Tetracycline and its derivatives should be strongly contraindicated for the treatment of gonorrhea.


Assuntos
Antibacterianos/farmacologia , Neisseria gonorrhoeae/efeitos dos fármacos , Humanos , Testes de Sensibilidade Microbiana
15.
An. bras. dermatol ; 97(1): 63-74, Jan.-Feb. 2022. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1360091

RESUMO

Abstract Generalized pustular psoriasis (von Zumbusch) is a rare and acute eruption characterized by multiple sterile pustules over an erythematous and edematous background, eventually associated with psoriasis vulgaris. Classically, it manifests as a potentially severe systemic picture and demands prompt diagnosis and intervention. The duration of each flare-up and intervals between the pustular episodes is extremely variable. Recently, genetic abnormalities have been identified mainly in the familial and early variants of this disease. The therapeutic arsenal is limited; however, new drugs being evaluated aim to control both pustular flare-ups and disease recurrences.


Assuntos
Humanos , Psoríase/diagnóstico , Psoríase/tratamento farmacológico , Dermatopatias Vesiculobolhosas , Exantema , Doença Aguda , Doença Crônica
17.
Diagn. tratamento ; 27(3): 80-4, jul-set. 2022. ilus, ilus
Artigo em Português | LILACS | ID: biblio-1380674

RESUMO

Contexto: A pandemia da doença do coronavírus (COVID-19) revelou uma miríade de manifestações sistêmicas e cutâneas possivelmente relacionadas à infecção por síndrome respiratória aguda grave ocasionada pelo coronavírus (SARS-CoV-2). O comprometimento pulmonar é a causa mais frequente de hospitalização e a progressão para síndrome respiratória aguda grave geralmente requer tratamento com ventilação mecânica na posição pronada. Períodos prolongados e repetidos de pronação aumentam o risco de complicações, incluindo úlcera de pressão, cegueira e neuropatia periférica. Descrição do caso: Relatamos três casos de complicações cutâneas relacionadas à ventilação em pronação avaliadas durante interconsultas no maior hospital terciário universitário da América Latina, e salientamos potenciais causas e medidas de prevenção. Discussão: Complicações da ventilação em pronação para tratamento da COVID-19 são provavelmente resultantes da interação entre múltiplos fatores, dentre os quais as condições clínicas do paciente, períodos prolongados na posição pronada e limitações para mudanças de decúbito. Conclusões: Medidas de prevenção para complicações da pronação e diagnóstico precoce são fundamentais para evitar aumento da morbidade e sequelas graves e irreversíveis associadas à COVID-19.


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Dermatopatias , Pronação , Ventilação Pulmonar , SARS-CoV-2 , COVID-19
20.
Autoimmun Rev ; 14(9): 769-73, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25936608

RESUMO

The Brazilian Societies of Rheumatology (SBR) and Dermatology (SBD), the Brazilian Federation of Gastroenterology (FBG) and the Brazilian Study Group on Inflammatory Bowel Disease (GEDIIB) gathered a group of their respective specialists on the topic of interest to discuss the most relevant issues regarding the clinical use of biosimilar medicines in Brazil. The main aim of that meeting was to prepare a document with recommendations to guide medical specialists and to help the national regulatory and policy-making agencies as concerns the authorization for marketing biosimilars used in autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, juvenile idiopathic arthritis and ulcerative colitis. In addition to considerations on the typical differences between innovator medicines and biosimilars, the specialists established a set of seven recommendations on regulatory advances related to clinical studies, indication extrapolation, nomenclature, interchangeability, automatic substitution and pharmacovigilance.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Medicamentos Biossimilares/uso terapêutico , Proteínas Recombinantes/uso terapêutico , Animais , Brasil , Gastroenteropatias/tratamento farmacológico , Humanos , Sociedades Médicas
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa